Search
                    Hypertension Paid Clinical Trials in Oklahoma
A listing of 6  Hypertension  clinical trials  in Oklahoma  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1 - 6 of 6
        
        
    
                The state of Oklahoma currently has 6 active clinical trials seeking participants for Hypertension research studies. These trials are conducted in various cities, including Oklahoma City, Tulsa, Norman and Edmond. 
            
                                Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Cardiovascular Disease Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Cardiovascular Disease
    
    
                            Conditions: 
                                    
        
            
                        Cardiovascular Disease
                    
                                    Featured Trial
                
                ASCVD A Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with ASCVD
    
    
                            Conditions: 
                                    
        
            
                        ASCVD A
                    
                                    
                        ASCVD
                    
                                    
                        Atherosclerotic Cardiovascular Disease (ASCVD)
                    
                                    
                        Atherosclerotic Cardiovascular Disease
                    
                                    
                        Atherosclerotic Cardiovascular Diseases
                    
                                    Featured Trial
                
                ASCVD B Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with ASCVD
    
    
                            Conditions: 
                                    
        
            
                        ASCVD B
                    
                                    
                        ASCVD
                    
                                    
                        Atherosclerotic Cardiovascular Disease
                    
                                    
                        Atherosclerotic Cardiovascular Disease (ASCVD)
                    
                                    
                        Atherosclerotic Cardiovascular Diseases
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    
                
                                    A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
                                
            
            
        Recruiting
                            
            
                This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empagliflozin, helps reduce cardiovascular risk in people with these conditions. The study will compare this combination to a placebo version of vicadrostat with empagliflozin.
Participants are put into 2 gro...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/19/2025
            
            Locations: Tekton Research-Edmond-68875, Edmond, Oklahoma  +2 locations         
        
        
            Conditions: Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
        
            
        
    
                
                                    BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
                                
            
            
        Recruiting
                            
            
                A prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel atrioventricular interval modulation (AVIM) algorithm downloaded into a dual-chamber Medtronic Astra/Azure pacemaker.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/15/2025
            
            Locations: University of Oklahoma, Oklahoma City, Oklahoma  +1 locations         
        
        
            Conditions: Hypertension, Hypertension, Systolic, Hypertension, Essential
        
            
        
    
                
                                    SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
                                
            
            
        Recruiting
                            
            
                The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation.
Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/12/2025
            
            Locations: Oklahoma Heart Hospital, Oklahoma City, Oklahoma         
        
        
            Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
        
            
        
    
                
                                    A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                08/07/2025
            
            Locations: Conrad Clinical Research, Edmond, Oklahoma         
        
        
            Conditions: Hypertension
        
            
        
    
                
                                    AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
                                
            
            
        Recruiting
                            
            
                This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or ocular hypertension             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/09/2025
            
            Locations: Oklahoma Eye Surgeons /ID# 252089, Oklahoma City, Oklahoma         
        
        
            Conditions: Open-angle Glaucoma, Ocular Hypertension
        
            
        
    
                
                                    Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
                                
            
            
        Recruiting
                            
            
                The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.             
        
        
    Gender:
                ALL
            Ages:
                Between 0 years and 20 years
            Trial Updated:
                03/11/2025
            
            Locations: Board of Regents of the University of Oklahoma, Oklahoma City, Oklahoma         
        
        
            Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Hemophilia, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
        
            
        
    1 - 6 of 6
            
            
        